Cerenome Director Richard Hawkins Receives 921 Shares via RSU Vesting

What Happened

• Richard J. Hawkins, a director of Cerenome, had 921 restricted stock units (RSUs) convert into 921 shares on 2026-10-01. The filing reports an acquisition of 921 shares at $0.00 and a simultaneous disposition entry of the related derivative instrument also at $0.00. No cash was paid or received in these transactions.

Key Details

• Transaction date: 2026-10-01
• Report filed/period of report: 2026-10-01 (no indication in the filing that it was late)
• Price: $0.00 per share (exercise/conversion)
• Shares acquired: 921 shares; a matching derivative disposition of 921 units is also reported
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnotes: F1 — each RSU represents a contingent right to one share; F2 — the RSU grant vests in four equal quarterly installments beginning July 1, 2026

Context

• This is a conversion/settlement of RSUs (derivative instruments) rather than an open-market purchase or sale. RSU settlements often show $0 exercise price because they represent the vesting of previously granted awards. Such transactions are routine for equity compensation and do not by themselves indicate a buy/sell signal.